Current and future molecular diagnostics in non-small-cell lung cancer

Li, Chun Man; Chu, Wing Ying; Wong, Di Lun; Tsang, Hin Fung; Tsui, Nancy B. Y.; Chan, Charles Ming Lok; Xue, Vivian Weiwen; Siu, Parco M.; Yung, Benjamin Yat‐Ming; Chan, Lawrence Wing Chi; Wong, Sze Chuen Cesar

doi:10.1586/14737159.2015.1063420

Cited by 14 publications

(9 citation statements)

References 144 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Harmonization is a long-term process that is ideally evidence-based yet also innovative, facilitates close interactions between the laboratory and clinician, and is a shared responsibility for all stakeholders (63). Industry involvement could help to establish pilot projects between healthcare institutions and insurers, and provide financial support through which to assess proposed diagnostic approaches for routine use, with a view to better understanding issues such as indications, tissue requirements, turnaround times, reliability, pitfalls, and costs (59,61,64,65).…”

Section: Challenge 4: Harmonization Of Diagnostics Involves Several Dmentioning

confidence: 99%

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

et al. 2020

View full text Add to dashboard Cite

The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predictive tumor markers that are necessary for optimal decision-making for today's available targeted or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular pathology was held in the Netherlands on December 10, 2018. The aims of the workshop were to facilitate cross-disciplinary discussions regarding standards of practice, and address recent developments and associated challenges that impact future practice. This paper presents a summary of the discussions and consensus opinions of the workshop participants on the initial challenges of harmonization of the detection and clinical use of predictive markers of NSCLC. A key theme identified was the need for broader and active participation of all stakeholders involved in molecular diagnostic services for NSCLC, including healthcare professionals across all disciplines, the hospitals and clinics involved in service delivery, healthcare insurers, and industry groups involved in diagnostic and treatment innovations. Such collaboration is essential to integrate different technologies into molecular diagnostics practice, to increase nationwide patient access to novel technologies, and to ensure consensus-preferred biomarkers are tested.

show abstract

Section: Challenge 4: Harmonization Of Diagnostics Involves Several Dmentioning

confidence: 99%

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Advances in genomic technology, such as NGS, have expanded the breadth and depth of the detection of gene alterations and have made it possible to analyze broad molecular profiling simultaneously, for discovering the comprehensive functional therapeutic targets in lung cancers [138][139][140]. The implementation of NGS permits the output of sequences with megabases to gigabases of genetic information in a single run using a limited amount of input DNA; this has enabled a shift in detection from single genes towards multigene panels [141].…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine

Han

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:In this era of precision medicine, molecular biology is becoming increasingly significant for the diagnosis and therapeutic management of non-small cell lung cancer. The specimen as the primary element of the whole testing flow is particularly important for maintaining the accuracy of gene alteration testing. Presently, the main sample types applied in routine diagnosis are tissue and cytology biopsies. Liquid biopsies are considered as the most promising alternatives when tissue and cytology samples are not available. Each sample type possesses its own strengths and weaknesses, pertaining to the disparity of sampling, preparation and preservation procedures, the heterogeneity of inter-or intratumors, the tumor cellularity (percentage and number of tumor cells) of specimens, etc., and none of them can individually be a "one size to fit all". Therefore, in this review, we summarized the strengths and weaknesses of different sample types that are widely used in clinical practice, offered solutions to reduce the negative impact of the samples and proposed an optimized strategy for choice of samples during the entire diagnostic course. We hope to provide valuable information to laboratories for choosing optimal clinical specimens to achieve comprehensive functional genomic landscapes and formulate individually tailored treatment plans for NSCLC patients that are in advanced stages.

show abstract

“…In recent years, the main treatments for advanced NSCLC have been chemotherapy, molecular-targeted therapy and developing immunotherapy (6)(7)(8). Although molecular targeted therapies have resulted important changes in the treatment of NSCLC, especially for adenocarcinoma, the odds of patients with lung cancer surviving for at least 5 years after diagnosis remain <15% (9). The pathogenesis behind lung cancer has not been fully elucidated, and research has shown that factors such as polygenes may be involved.…”

Section: Introductionmentioning

confidence: 99%

Effect and mechanism of miR‑146a on malignant biological behaviors of lung adenocarcinoma cell line

et al. 2020

View full text Add to dashboard Cite

The aim of the present study was to assess the expression of microRNA-146a (miR-146a) in human lung adenocarcinoma cells, its effect on cellular behaviors, and the underlying molecular mechanisms. Reverse transcription-quantitative PCR (RT-qPCR) was used to measure miR-146a expression in the human normal lung epithelial cell line, BEAS-2B, and human lung adenocarcinoma cell lines, A549, PC-9 and H1299, to determine whether miR-146a acts as an oncogene or anti-oncogene. miR-146a mimics were transfected into target cells to observe the proliferation, apoptosis, invasion and migration of human lung adenocarcinoma cells. The target genes of miR-146a were predicted using bioinformatics analysis, and binding sites were validated by dual-luciferase reporter assay. Target gene expression at the mRNA and protein levels was measured by RT-qPCR and western blot analysis, respectively. The expression levels of miR-146a in human lung adenocarcinoma cell lines were lower than its expression in BEAS-2B (P<0.01). A549 cell line is a EGFR wild-type lung adenocarcinoma cell line, which is also the most widely studied in NSCLC, and therefore this was chosen as the target cell line for further investigation. Overexpression of miR-146a in A549 cells can inhibit cell proliferation (P<0.05), promote apoptosis (P<0.05), and reduce the cells' migratory ability (P<0.01). Bioinformatics prediction indicated that interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) are the target genes of miR-146a. Dual-luciferase reporter assay showed that miR-146a could specifically bind to 3'-untranslated regions of IRAK1 and TRAF6. The protein and mRNA levels of IRAK1 and TRAF6 were significantly downregulated after miR-146a overexpression in A549 cells (P<0.01). The results of this study demonstrated that the expression of miR-146a in human lung adenocarcinoma cells was significantly lower than in normal lung epithelial cells, indicating that miR-146a acts as an anti-oncogene. miR-146a suppresses the proliferation and migration of human lung adenocarcinoma cells by downregulating the expression of IRAK1 and TRAF6.

show abstract

Current and future molecular diagnostics in non-small-cell lung cancer

Cited by 14 publications

References 144 publications

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine

Effect and mechanism of miR‑146a on malignant biological behaviors of lung adenocarcinoma cell line

Contact Info

Product

Resources

About